[Treatment of hereditary angioneurotic edema with androgens].
Hereditary angioedema (HANE) is a rare, life-threatening disease due to the deficiency of C1 inhibitor (C1 Inh). Androgen therapy has been recently shown to be effective for prophylaxis of Hane attacks. Since life-long androgen therapy may be hazardous, this study was designed to define the minimal doses required for effectiveness. Ten patients from six different families were treated during cumulative 73 months by danazol and/for methandrostenolone. One tablet/day of either drug was the minimal requirement to prevent any attack in all patients. When 3 tablets/day were given, complement abnormalities were simultaneously rapidly reversed. When 1 tablet/day was given the biological effect was barely detectable, except for C2. Serum C2 levels may, therefore, represent the best criteria of androgen therapy effectiveness. Thus, an excellent clinical result can be obtained with much lower doses of androgens than previously stated. This result seemed important with respect to the serious dose-dependent risk of androgens.
D000328:Adult; D000368:Aged; D000728:Androgens / Q000008:administration & dosage* / Q000627:therapeutic use; D000799:Angioedema / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D003174:Complement C1 Inactivator Proteins / Q000032:analysis; D003175:Complement C2 / Q000032:analysis; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008696:Methandrostenolone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged
D000728:Androgens; D003174:Complement C1 Inactivator Proteins; D003175:Complement C2; D003176:Complement C3; D003181:Complement C4; D008696:Methandrostenolone; D003613:Danazol
Traitement de l'oedème angio-neurotique héréditaire par les androgènes.